Combination therapy with CDK4/6 and mTOR inhibitors could also enable the use of lower doses, thus diminishing adverse effects and toxicity in patients, as neutropenia, leukopenia, thrombocytopenia, anemia, fatigue or diarrhea. Here, CDK4 is linked to neutropenia.